{"id":46864,"date":"2023-10-06T14:15:22","date_gmt":"2023-10-06T13:15:22","guid":{"rendered":"https:\/\/grayling.com\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/"},"modified":"2023-10-06T14:15:22","modified_gmt":"2023-10-06T13:15:22","slug":"grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last","status":"publish","type":"post","link":"https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/","title":{"rendered":"Grayling research\u00a0reveals increasing\u00a0goodwill\u00a0towards\u00a0pharma: But can it last?\u00a0"},"content":{"rendered":"

As the world continues to tackle the Covid-19 pandemic,\u00a0Grayling\u00a0launched a global\u00a0report\u00a0exploring\u00a0how people across the world perceive the role and reputation of the pharmaceutical industry.\u00a0Kathryn Ager<\/a>, Head of\u00a0Health at Grayling<\/strong>, looks at\u00a0the findings and what they mean for the sector.<\/p>\n

How is\u00a0public awareness of \u2013 and trust in \u2013 big pharma companies changing as the pandemic evolves? How is the relationship between pharmaceutical companies and governments changing and what does this mean for the future of the industry? How can pharmaceutical companies improve their communication with stakeholders in the medical industry, government and the public at large?<\/p>\n

Grayling wanted to explore\u00a0these questions, so we\u00a0surveyed\u00a0the\u00a0general\u00a0public\u00a0in the UK, US, France, Germany, Russia and China\u00a0to investigate how their attitudes towards pharma have evolved*. We also\u00a0spoke to 14\u00a0senior decision-makers within the health sector\u00a0including representatives from the industry, patient groups and policy makers\u00a0to\u00a0gauge their views.\u00a0The results of our research can be found in our latest report,\u00a0\u2018Emerging from Covid-19: What Next for the Pharmaceutical Industry?<\/a>\u2019\u00a0but I\u2019d like to\u00a0highlight\u00a0a few\u00a0standouts.<\/p>\n

The\u00a0perception of\u00a0pharma\u00a0has\u00a0improved during the pandemic\u00a0<\/strong><\/p>\n

We observe that\u00a0the\u00a0public\u00a0perception of pharma companies has largely been enhanced\u00a0during the pandemic, especially in countries where Covid vaccine rollouts have been most successful.<\/p>\n

Nearly two-thirds (63%) say that the pharmaceutical industry has a positive impact on society. Nearly half (49%) say they view the pharmaceutical industry more positively than before the pandemic. This was particularly evident in markets such as China,\u00a0where nearly nine in ten (89%) people felt more positive towards the industry. Meanwhile,\u00a0just a third (33%) of French people reported the same.<\/p>\n

Just 14% worldwide say they feel the pharma sector has a negative impact on society. Men\u00a0are\u00a0narrowly more positive\u00a0towards pharma\u00a0overall than women.<\/p>\n

Speaking to our expert interviewees, the consensus was largely that the perception of pharma \u2013 together with an understanding of what it does and how it works – had improved.\u00a0The challenge is how to make this goodwill last.<\/p>\n

In terms of\u00a0reputation\u00a0for individual\u00a0pharma brands, the picture is mixed\u00a0<\/strong><\/p>\n

Has the public heard of the leading Covid vaccine manufacturers and, if so, what do they think about them?\u00a0One in five (21%) people say they have heard of AstraZeneca because of the pandemic, 15% say Pfizer and more than one in ten say they now know Johnson & Johnson (11%) and Sanofi (10%).<\/p>\n

Pfizer enjoys a healthy approval rating (60% positive) among those who have heard of the brand.\u00a0\u00a0Perhaps not unexpectedly\u00a0AstraZeneca is experiencing more negative perceptions, possibly due to its\u00a0legal battles with the EU<\/a>,\u00a0question marks over the accuracy of its data in the US<\/a>\u00a0and\u00a0reported links to rare blood clots<\/a>.<\/p>\n

More than a third (36%) of people said what they heard about AstraZeneca was negative, compared to Johnson & Johnson (21%) and Sanofi (15%).\u00a0Negativity towards AstraZeneca was highest in France (46%) and Germany (42%) but lowest in the US (nine percent).<\/p>\n

\u2018Vaccine nationalism\u2019 is strong, but it varies wildly from country to country\u00a0<\/strong><\/p>\n

There\u2019s no doubt that Covid-19, and therefore the vaccines associated with it, have become politicised. Important national and local elections in the US, Israel, Netherlands, Spain and UK have been influenced by\u00a0governments\u2019\u00a0handling of the crisis.<\/p>\n

Two of our interviewees, including a former UK politician, say\u00a0that \u2018vaccine nationalism\u2019 is inevitable as countries look to protect their populations.<\/p>\n

Our research finds\u00a0that people in the UK were far less attached to the idea that a vaccine\u00a0had\u00a0to be produced in their country to be trustworthy than other countries. Just under half (49%) said it was important that a vaccine was developed in their country for them to trust it, compared to China (88%), Germany (68%) and France (65%).<\/p>\n

Pharma has an opportunity\u00a0to build on the goodwill, but must demonstrate \u2018purpose\u2019\u00a0<\/strong><\/p>\n

The pandemic has accelerated progress towards more compassionate business models, where\u00a0organisations\u00a0are finding a purpose beyond purely prioritising profits. This \u2018New Collectivism<\/a>\u2019\u00a0embeds\u00a0greater environmental, social and governance (ESG) responsibility into company culture.<\/p>\n

This quest for a \u2018higher purpose\u2019 for pharma is reflected in the findings of our global survey. More than half (55%) said they would be more likely to trust a Covid-19 vaccine if the manufacturer had promised not to seek to make a profit from it. Women (58%) are more likely than men (52%) to trust a not-for-profit vaccine.<\/p>\n

Changing the conversation around pharma\u00a0<\/strong><\/p>\n

While pharmaceutical companies that produced vaccines for Covid-19 have often taken centre stage over the past year, our report clearly shows there is opportunity for the\u00a0entire\u00a0industry to\u00a0get behind\u00a0this\u00a0increased understanding\u00a0and appreciation\u00a0and use it\u00a0as a force for good.\u00a0\u00a0\u00a0The healthcare experts we interviewed agreed\u00a0that the industry now has a platform that it didn\u2019t have prior to the pandemic.\u00a0This provides\u00a0a golden opportunity to discuss its research and development (R&D), highlight its solutions to wider health issues,\u00a0and address traditional questions around pharma, such as access and pricing.\u00a0 And those that can do this best will no doubt prosper now\u00a0and in the months\u00a0and years ahead.<\/p>\n

Please click here to download your copy of our report \u2013 Emerging from Covid-19: What next for the pharmaceutical industry?<\/a>\u00a0<\/strong><\/p>\n

And if your healthcare organisation needs expert\u00a0communications counsel, please\u00a0contact me<\/a>.\u00a0<\/strong><\/p>\n

 <\/p>\n

*Grayling\u00a0commissioned Opinium Research to survey\u00a03,000 members of the public\u00a0in the UK, US, France, Germany, Russia and China.<\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"As the world continues to tackle the Covid-19 pandemic,\u00a0Grayling\u00a0launched a global\u00a0report\u00a0exploring\u00a0how people across the world perceive the role and reputation of the pharmaceutical industry.\u00a0Kathryn Ager, Head of\u00a0Health at Grayling, looks at\u00a0the findings and what they mean for the sector. How is\u00a0public awareness of \u2013 and trust in \u2013 big pharma companies changing as the pandemic…","protected":false},"author":5,"featured_media":44911,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[544],"tags":[],"class_list":["post-46864","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized-de-2","Sector-healthcare"],"acf":[],"yoast_head":"\nGrayling research\u00a0reveals increasing\u00a0goodwill\u00a0towards\u00a0pharma: But can it last?\u00a0 - Grayling<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Grayling research\u00a0reveals increasing\u00a0goodwill\u00a0towards\u00a0pharma: But can it last?\u00a0 - Grayling\" \/>\n<meta property=\"og:description\" content=\"As the world continues to tackle the Covid-19 pandemic,\u00a0Grayling\u00a0launched a global\u00a0report\u00a0exploring\u00a0how people across the world perceive the role and reputation of the pharmaceutical industry.\u00a0Kathryn Ager, Head of\u00a0Health at Grayling, looks at\u00a0the findings and what they mean for the sector. How is\u00a0public awareness of \u2013 and trust in \u2013 big pharma companies changing as the pandemic...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/\" \/>\n<meta property=\"og:site_name\" content=\"Grayling\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-06T13:15:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/grayling.com\/wp-content\/uploads\/2023\/10\/grayling_global_health_report_image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Ayer Mehmet\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ayer Mehmet\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/\"},\"author\":{\"name\":\"Ayer Mehmet\",\"@id\":\"https:\/\/grayling.com\/es\/#\/schema\/person\/251e08a9ee207bed4560033529fa47ce\"},\"headline\":\"Grayling research\u00a0reveals increasing\u00a0goodwill\u00a0towards\u00a0pharma: But can it last?\u00a0\",\"datePublished\":\"2023-10-06T13:15:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/\"},\"wordCount\":912,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/grayling.com\/es\/#organization\"},\"image\":{\"@id\":\"https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/grayling.com\/wp-content\/uploads\/2023\/10\/grayling_global_health_report_image.jpg\",\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/\",\"url\":\"https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/\",\"name\":\"Grayling research\u00a0reveals increasing\u00a0goodwill\u00a0towards\u00a0pharma: But can it last?\u00a0 - Grayling\",\"isPartOf\":{\"@id\":\"https:\/\/grayling.com\/es\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/grayling.com\/wp-content\/uploads\/2023\/10\/grayling_global_health_report_image.jpg\",\"datePublished\":\"2023-10-06T13:15:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/#primaryimage\",\"url\":\"https:\/\/grayling.com\/wp-content\/uploads\/2023\/10\/grayling_global_health_report_image.jpg\",\"contentUrl\":\"https:\/\/grayling.com\/wp-content\/uploads\/2023\/10\/grayling_global_health_report_image.jpg\",\"width\":1920,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/grayling.com\/es\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Grayling research\u00a0reveals increasing\u00a0goodwill\u00a0towards\u00a0pharma: But can it last?\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/grayling.com\/es\/#website\",\"url\":\"https:\/\/grayling.com\/es\/\",\"name\":\"Grayling\",\"description\":\"We create advantage\",\"publisher\":{\"@id\":\"https:\/\/grayling.com\/es\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/grayling.com\/es\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/grayling.com\/es\/#organization\",\"name\":\"Grayling\",\"url\":\"https:\/\/grayling.com\/es\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/grayling.com\/es\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/grayling.com\/wp-content\/uploads\/2020\/08\/logo.jpg\",\"contentUrl\":\"https:\/\/grayling.com\/wp-content\/uploads\/2020\/08\/logo.jpg\",\"width\":2009,\"height\":510,\"caption\":\"Grayling\"},\"image\":{\"@id\":\"https:\/\/grayling.com\/es\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/grayling.com\/es\/#\/schema\/person\/251e08a9ee207bed4560033529fa47ce\",\"name\":\"Ayer Mehmet\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/grayling.com\/es\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/dfe275d9acede3df4c4453ea89cc4a8af78c99dc409fe1e6407c482a329cbaaf?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/dfe275d9acede3df4c4453ea89cc4a8af78c99dc409fe1e6407c482a329cbaaf?s=96&d=mm&r=g\",\"caption\":\"Ayer Mehmet\"},\"url\":\"https:\/\/grayling.com\/es\/news-and-views\/author\/ayer-mehmetgrayling-com\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Grayling research\u00a0reveals increasing\u00a0goodwill\u00a0towards\u00a0pharma: But can it last?\u00a0 - Grayling","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/","og_locale":"es_ES","og_type":"article","og_title":"Grayling research\u00a0reveals increasing\u00a0goodwill\u00a0towards\u00a0pharma: But can it last?\u00a0 - Grayling","og_description":"As the world continues to tackle the Covid-19 pandemic,\u00a0Grayling\u00a0launched a global\u00a0report\u00a0exploring\u00a0how people across the world perceive the role and reputation of the pharmaceutical industry.\u00a0Kathryn Ager, Head of\u00a0Health at Grayling, looks at\u00a0the findings and what they mean for the sector. How is\u00a0public awareness of \u2013 and trust in \u2013 big pharma companies changing as the pandemic...","og_url":"https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/","og_site_name":"Grayling","article_published_time":"2023-10-06T13:15:22+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/grayling.com\/wp-content\/uploads\/2023\/10\/grayling_global_health_report_image.jpg","type":"image\/jpeg"}],"author":"Ayer Mehmet","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Ayer Mehmet","Tiempo de lectura":"5 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/#article","isPartOf":{"@id":"https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/"},"author":{"name":"Ayer Mehmet","@id":"https:\/\/grayling.com\/es\/#\/schema\/person\/251e08a9ee207bed4560033529fa47ce"},"headline":"Grayling research\u00a0reveals increasing\u00a0goodwill\u00a0towards\u00a0pharma: But can it last?\u00a0","datePublished":"2023-10-06T13:15:22+00:00","mainEntityOfPage":{"@id":"https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/"},"wordCount":912,"commentCount":0,"publisher":{"@id":"https:\/\/grayling.com\/es\/#organization"},"image":{"@id":"https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/#primaryimage"},"thumbnailUrl":"https:\/\/grayling.com\/wp-content\/uploads\/2023\/10\/grayling_global_health_report_image.jpg","articleSection":["Uncategorized"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/","url":"https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/","name":"Grayling research\u00a0reveals increasing\u00a0goodwill\u00a0towards\u00a0pharma: But can it last?\u00a0 - Grayling","isPartOf":{"@id":"https:\/\/grayling.com\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/#primaryimage"},"image":{"@id":"https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/#primaryimage"},"thumbnailUrl":"https:\/\/grayling.com\/wp-content\/uploads\/2023\/10\/grayling_global_health_report_image.jpg","datePublished":"2023-10-06T13:15:22+00:00","breadcrumb":{"@id":"https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/#primaryimage","url":"https:\/\/grayling.com\/wp-content\/uploads\/2023\/10\/grayling_global_health_report_image.jpg","contentUrl":"https:\/\/grayling.com\/wp-content\/uploads\/2023\/10\/grayling_global_health_report_image.jpg","width":1920,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/grayling.com\/es\/news-and-views\/grayling-research-reveals-increasing-goodwill-towards-pharma-but-can-it-last\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/grayling.com\/es\/"},{"@type":"ListItem","position":2,"name":"Grayling research\u00a0reveals increasing\u00a0goodwill\u00a0towards\u00a0pharma: But can it last?\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/grayling.com\/es\/#website","url":"https:\/\/grayling.com\/es\/","name":"Grayling","description":"We create advantage","publisher":{"@id":"https:\/\/grayling.com\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/grayling.com\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/grayling.com\/es\/#organization","name":"Grayling","url":"https:\/\/grayling.com\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/grayling.com\/es\/#\/schema\/logo\/image\/","url":"https:\/\/grayling.com\/wp-content\/uploads\/2020\/08\/logo.jpg","contentUrl":"https:\/\/grayling.com\/wp-content\/uploads\/2020\/08\/logo.jpg","width":2009,"height":510,"caption":"Grayling"},"image":{"@id":"https:\/\/grayling.com\/es\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/grayling.com\/es\/#\/schema\/person\/251e08a9ee207bed4560033529fa47ce","name":"Ayer Mehmet","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/grayling.com\/es\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/dfe275d9acede3df4c4453ea89cc4a8af78c99dc409fe1e6407c482a329cbaaf?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/dfe275d9acede3df4c4453ea89cc4a8af78c99dc409fe1e6407c482a329cbaaf?s=96&d=mm&r=g","caption":"Ayer Mehmet"},"url":"https:\/\/grayling.com\/es\/news-and-views\/author\/ayer-mehmetgrayling-com\/"}]}},"_links":{"self":[{"href":"https:\/\/grayling.com\/es\/wp-json\/wp\/v2\/posts\/46864","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grayling.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/grayling.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/grayling.com\/es\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/grayling.com\/es\/wp-json\/wp\/v2\/comments?post=46864"}],"version-history":[{"count":0,"href":"https:\/\/grayling.com\/es\/wp-json\/wp\/v2\/posts\/46864\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grayling.com\/es\/wp-json\/wp\/v2\/media\/44911"}],"wp:attachment":[{"href":"https:\/\/grayling.com\/es\/wp-json\/wp\/v2\/media?parent=46864"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/grayling.com\/es\/wp-json\/wp\/v2\/categories?post=46864"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/grayling.com\/es\/wp-json\/wp\/v2\/tags?post=46864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}